Levamlodipine Besylate/Valsartan (Sunshine Novo)

苯磺酸左旋氨氯地平/缬沙坦 (北京阳光诺和)

Report date: 2024/02/08 20:00:35

Base Information

Drug NameLevamlodipine Besylate/Valsartan (Sunshine Novo)
Drug Alias NameNHKC-1
ClassificationSmall molecules
Mechanisms of ActionVoltage-gated calcium channel blockersAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Sunshine Novo Pharmaceutical Research Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Baiao Pharmaceuticals Co LtdBeijing Sunshine Novo Pharmaceutical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A